<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-102 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-102</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-102</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-2.html">extraction-schema-2</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of EGFR mutation frequencies in different ethnic or geographic populations, particularly comparing East Asian and non-Asian populations, along with any proposed mechanisms, risk factors, or explanations for these differences.</div>
                <p><strong>Paper ID:</strong> paper-24127652</p>
                <p><strong>Paper Title:</strong> Spectrum of EGFR gene mutations and ALK rearrangements in lung cancer patients in Turkey</p>
                <p><strong>Paper Abstract:</strong> The EGFR gene and ALK rearrangements are two genetic drivers of non-small cell lung cancer (NSCLC). The frequency of EGFR mutations and ALK rearrangement varies according to not only ethnicity but also gender, smoking status and the histological type of NSCLC. In the present study, we demonstrated the distribution of EGFR mutations in 132 NSCLC patients by using a pyrosequencing technique and the distribution of ALK rearrangements in 51 NSCLC patients by using fluorescent in situ hybridization technique in Turkey. Additionally, we compared the clinicopathological data of NSCLC patients with the mutation status of EGFR in their cancerous tissues. Both EGFR mutations and ALK rearrangements were identified in 19 (14.39 %) and 1 (1.96 %) patients, respectively. We found EGFR mutations in codon 861, 719 and 858 with the ratios of 10.52 % (2/19), 10.52 % (2/19) and 31.58 % (6/19), respectively, and deletion of exon 19 in 47.37 % (9/19) of the patients. We found the frequency of EGFR mutations to be significantly higher in female patients and nonsmokers (p = 0.043, p = 0.027, respectively). Consequently, we found EGFR mutations to be more frequent in female patients and nonsmokers. Future studies on larger patient groups would provide more accurate data to exhibit the relationship between EGFR mutations and ALK rearrangements and the clinicopathological status.</p>
                <p><strong>Cost:</strong> 0.009</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e102.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e102.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of EGFR mutation frequencies in different ethnic or geographic populations, particularly comparing East Asian and non-Asian populations, along with any proposed mechanisms, risk factors, or explanations for these differences.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Turkey (this study)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Spectrum of EGFR gene mutations and ALK rearrangements in lung cancer patients in Turkey</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Single-center retrospective study of 132 NSCLC patients in Turkey reporting EGFR mutation prevalence, exon- and codon-level breakdown, and associations with clinicopathological factors (gender, smoking).</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>Turkish NSCLC patients (single-center cohort at UludaÄŸ University, Turkey); 132 patients analyzed for EGFR mutations</td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_frequency</strong></td>
                            <td>14.39% overall (19/132). Among the 19 EGFR-mutant tumors: exon 19 deletions 47.37% (9/19); codon 858 mutations 31.58% (6/19); codon 861 mutations 10.52% (2/19); codon 719 mutations 10.52% (2/19). Among exon 19 deletions delE746-A750 accounted for 42.11% of all mutations (8/19) and delL747-p753,InsS for 5.26% (1/19). One patient had codon 719 plus codon 790 mutation.</td>
                        </tr>
                        <tr>
                            <td><strong>comparison_populations</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>specific_mutation_types</strong></td>
                            <td>Exon 19 deletions (delE746-A750, delL747-p753,InsS), L858R (exon 21 / codon 858), mutations at codons 861 and 719; a codon 790 mutation co-occurring with codon 719 in one patient.</td>
                        </tr>
                        <tr>
                            <td><strong>smoking_status_association</strong></td>
                            <td>EGFR mutations significantly more frequent in never-smokers vs ever-smokers (mutation frequency: 21.7% of never-smokers had EGFR mutations vs 7.1% of ever-smokers; p = 0.027).</td>
                        </tr>
                        <tr>
                            <td><strong>environmental_factors</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>genetic_factors</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>biological_mechanisms</strong></td>
                            <td>No specific molecular mechanism for ethnic/geographic differences is proposed; general EGFR pathway biology is described (EGFR activates RAS-RAF-MEK-MAPK, PI3K-PTEN-AKT, and STAT pathways) but not tied mechanistically to the observed population differences.</td>
                        </tr>
                        <tr>
                            <td><strong>lung_cancer_subtype</strong></td>
                            <td>Non-small cell lung cancer (NSCLC), predominantly adenocarcinoma (127/132, 96.2%).</td>
                        </tr>
                        <tr>
                            <td><strong>demographic_factors</strong></td>
                            <td>Median age 60 (range 31-83); EGFR mutations significantly more frequent in females (26.5% of females vs 10.2% of males; p = 0.043); higher prevalence in never-smokers as above.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation</strong></td>
                            <td>Authors attribute differences in EGFR mutation prevalence across studies partly to (1) differences in patient populations (e.g., gender and smoking distributions), (2) diversity in sensitivity and methods of mutation detection techniques, and (3) dependence of reported mutation rates on the prevalence of smoking in the cohort. They also note small sample size and single-center design as limitations affecting observed rates.</td>
                        </tr>
                        <tr>
                            <td><strong>counterevidence_or_confounds</strong></td>
                            <td>Study limitations cited that could confound prevalence estimates include single-center design, relatively small sample size, and that mutation rate depends on cohort smoking prevalence; no direct causal evidence explaining ethnic differences is provided.</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e102.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e102.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of EGFR mutation frequencies in different ethnic or geographic populations, particularly comparing East Asian and non-Asian populations, along with any proposed mechanisms, risk factors, or explanations for these differences.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Asian vs Western (literature summary)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Reported EGFR mutation prevalence in East Asian versus Western (non-Asian) populations (summary from cited literature)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Literature-cited summary in this paper that EGFR-activating mutation prevalence is substantially higher in East Asian populations compared with unselected Western populations, with additional exon-distribution data from a large aggregated analysis.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>Reported populations in cited literature: 'Asian' / 'East Asian' populations and 'unselected Western' (non-Asian) populations; also large aggregated dataset of 12,244 patients from Murray et al.</td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_frequency</strong></td>
                            <td>Cited literature summary: unselected Western patients ~10-15%; Asian populations ~30-40%. From Murray et al. aggregated data (12,244 patients with 3,381 EGFR mutations): exon 19 mutations ~50%, exon 21 mutations ~40%, exon 20 ~6%, exon 18 ~4%; L858R and delE746-A750 constituted 32.8% and 24.3% of mutations respectively; ~50% of mutations were exon 19 deletions or deletion-insertions.</td>
                        </tr>
                        <tr>
                            <td><strong>comparison_populations</strong></td>
                            <td>Asian (East Asian): ~30-40% EGFR mutation prevalence; Western (unselected): ~10-15% prevalence. (Reported as literature values within the paper.)</td>
                        </tr>
                        <tr>
                            <td><strong>specific_mutation_types</strong></td>
                            <td>Exon 19 deletions (multiple variants, common delE746-A750), exon 21 L858R, exon 20 insertions/duplications (~5-10% of mutations, often TKI-resistant), exon 18 activating mutations; distribution percentages as above from Murray et al.</td>
                        </tr>
                        <tr>
                            <td><strong>smoking_status_association</strong></td>
                            <td>Cited literature indicates EGFR mutations are associated with 'never-smoker' status; EGFR mutations are more frequent in never-smokers vs smokers (examples cited: 51% vs 10% in one literature summary).</td>
                        </tr>
                        <tr>
                            <td><strong>environmental_factors</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>genetic_factors</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>biological_mechanisms</strong></td>
                            <td>The paper does not provide specific genetic or molecular mechanisms explaining the higher prevalence in East Asians; it only notes associations (female, never-smoker, adenocarcinoma) and discusses EGFR pathway biology generally. No ethnicity-specific molecular mechanism is offered.</td>
                        </tr>
                        <tr>
                            <td><strong>lung_cancer_subtype</strong></td>
                            <td>Non-small cell lung cancer, particularly adenocarcinoma (EGFR mutations enriched in adenocarcinoma vs other histologies: cited as ~40% vs 3% in some literature).</td>
                        </tr>
                        <tr>
                            <td><strong>demographic_factors</strong></td>
                            <td>Cited literature notes higher EGFR mutation prevalence in females and never-smokers; literature numbers cited include female vs male rates (42% vs 14%) and never-smoker vs smoker rates (51% vs 10%) from prior reviews/studies.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation</strong></td>
                            <td>The paper suggests that reported ethnic/geographic differences likely reflect (a) differences in patient selection and population characteristics (gender, smoking prevalence, histology), (b) variability in mutation-detection methodologies and their sensitivities across studies, and (c) cohort-specific factors (e.g., smoking prevalence). The paper does not provide a direct biological or environmental causal explanation for the East Asian versus non-Asian disparity.</td>
                        </tr>
                        <tr>
                            <td><strong>counterevidence_or_confounds</strong></td>
                            <td>Authors cite study heterogeneity and methodological sensitivity as confounds; they also reference studies (e.g., some reports where gender differences were not observed) that show variability in associations. The paper notes that sample size, single-center data, and cohort smoking prevalence can confound comparisons across populations.</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>Somatic mutations of the tyrosine kinase domain of epidermal growth factor receptor and tyrosine kinase inhibitor response to TKIs in nonsmall cell lung cancer: an analytical database. <em>(Rating: 2)</em></li>
                <li>A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). <em>(Rating: 2)</em></li>
                <li>Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. <em>(Rating: 2)</em></li>
                <li>EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. <em>(Rating: 2)</em></li>
                <li>The epidemiology of EGFR mutations. <em>(Rating: 2)</em></li>
                <li>Relationship between epidermal growth factor receptor gene mutations and clinicopathologic features in patients with non-small cell lung cancer. <em>(Rating: 2)</em></li>
                <li>The prevalence of EGFR mutations in non-small cell lung cancer in an unselected Caucasian population. <em>(Rating: 1)</em></li>
                <li>Relationship between epidermal growth factor receptor gene mutations and clinicopathological features in patients with non-small cell lung cancer in western Turkey. <em>(Rating: 1)</em></li>
                <li>EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. <em>(Rating: 2)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>